Indonesia vs Mozambique: Treatment coverage for lymphatic filariasis

Indonesia
51.8%
in 2024
Mozambique
58.3%
in 2024
Indonesia rank
41st
Mozambique rank
38th

Treatment coverage for lymphatic filariasis over time

  • Indonesia
  • Mozambique
020406080200220132024

How they compare

Mozambique currently reports 58.3% against 51.8% in Indonesia, a difference of 6.5%.

That makes Mozambique's figure about 1.1 times Indonesia's.

The two have swapped places 9 times across 16 shared years of data; in 2009 it was Indonesia ahead.

Indonesia ranks 41st and Mozambique ranks 38th of 66 countries.

Across the 3 decades both report, Indonesia averaged higher in 2 and Mozambique in 1.

Head to head by decade

Decade Indonesia Mozambique Difference Ahead
2000s 15.4% 10.3% 5.0% Indonesia
2010s 45.8% 49.7% 3.9% Mozambique
2020s 51.9% 40.3% 11.6% Indonesia

Averages of every year both report within each decade.

Frequently asked questions

Which has higher treatment coverage for lymphatic filariasis, Indonesia or Mozambique?
Mozambique, at 58.3% against 51.8% in Indonesia as of 2024.
What is the difference in treatment coverage for lymphatic filariasis between Indonesia and Mozambique?
6.5%, with Mozambique ahead.
How many years of comparable data are there for Indonesia and Mozambique?
16 years are reported by both, from 2009 to 2024.
How do Indonesia and Mozambique rank globally for treatment coverage for lymphatic filariasis?
Indonesia ranks 41st and Mozambique ranks 38th of 66 countries.
Where does this data come from?
World Health Organization (2025) – with minor processing by Our World in Data, published as Treatment coverage for lymphatic filariasis. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Treatment coverage for lymphatic filariasis
Unit
%
Source
World Health Organization (2025) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
66 places, 966 data points, 1999–2024
Last refreshed

Drug coverage out of estimated population who require it.